Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Patients With Advanced Or Metastatic Merkel Cell Carcinoma

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Patients With Advanced Or Metastatic Merkel Cell Carcinoma

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 06 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IFx 2.0 (Primary) ; Pembrolizumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors TuHURA Biosciences

Most Recent Events

  • 28 Apr 2025 According to TuHURA Biosciences media release, the company look forward to anticipated initiation of Phase 3 accelerated approval trial in first line treatment of patients with advanced or metastatic Merkel cell carcinoma targeted for later this quarter.
  • 17 Oct 2024 According to a TuHURA Biosciences media release, company announced merger with Kintara Therapeutics, Inc. and the combined company will operate under the name "TuHURA Biosciences, Inc.''
  • 17 Oct 2024 According to TuHURA Biosciences media release, The Company is preparing to initiate a single Phase 3 accelerated approval registration trial in the first half of 2025 for treatment of 1st line Merkel Cell carcinoma under SPA agreement with FDA.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top